Ds. Chervinsky et al., Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: Parallels with E2A-deficient mice, MOL CELL B, 19(7), 1999, pp. 5025-5035
The gene most commonly activated by chromosomal rearrangements in patients
with T-cell acute lymphoblastic leukemia (T-ALL) is SCL/tal. In collaborati
on with LMO1 or LMO2, the thymic expression of SCL/tal leads to T-ALL at a
young age with a high degree of penetrance in transgenic mice. We now show
that SCL LMO1 double-transgenic mice display thymocyte developmental abnorm
alities in terms of proliferation, apoptosis, clonality, and immunophenotyp
e prior to the onset of a frank malignancy. At 4 weeks of age, thymocytes f
rom SCL LMO1 mice show 70% fewer total thymocytes, with increased rates of
both proliferation and apoptosis, than control thymocytes. At this age, a c
lonal population of thymocytes begins to populate the thymus, as evidenced
by oligoclonal T-cell-receptor gene rearrangements. Also, there is a dramat
ic increase in immature CD44(+) CD25(-) cells, a decrease in the more matur
e CD4(+) CD8(+) cells, and development of an abnormal CD44(+) CD8(+) popula
tion. An identical pattern of premalignant changes is seen with either a fu
ll-length SCL protein or an amino-terminal truncated protein which lacks th
e SCL transactivation domain, demonstrating that the amino-terminal portion
of SCL is not important for leukemogenesis. Lastly, we show that the T-ALL
which develop in the SCL LMO1 mice are strikingly similar to those which d
evelop in E2A null mice, supporting the hypothesis that SCL exerts its onco
genic action through a functional inactivation of E proteins.